ClinicalTrials.gg
CompletedNCT04429503PHOTONUpdated Aug 8, 2025Results posted

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

A Phase 2/3 interventional study of aflibercept and High-dose aflibercept in Diabetic Macular Edema, Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus, sponsored by Regeneron Pharmaceuticals. Completed at 138 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
31st of 1,242
660 · median 40
Started
2020
with 70 others
Phase 2/3
20 of 1,458
none open now
Registered
1,037th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 31st largest by enrollment of the 1,242 interventional ones that give a count, is one of 71 that started in 2020, is one of 20 in phase 2/3, and was the 1,037th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.

The secondary objectives of the study are as follows:

  • To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response
  • To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept
03

Conditions studied

  • Diabetic Macular Edema
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diabetic macular edema (DME) with central involvement in the study eye
  • Best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye with decreased vision determined to be primarily the result of DME
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed by study participant or legally acceptable representative

Extension Phase: All randomized patients that complete visit 26, week 96, as long as the patient 1) provides informed consent and 2) no treatment for DME has been given in the study eye other than the randomized study treatment.

Key Exclusion Criteria:

  • Evidence of macular edema due to any cause other than diabetes mellitus in either eye
  • Active proliferative diabetic retinopathy in the study eye
  • IVT anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) or panretinal laser photocoagulation (PRP) /macular laser photocoagulation within 12 weeks (84 days) or intraocular or periocular within 16 weeks (112 days) of the screening visit in the study eye
  • Prior IVT agents in either eye (eg, anti-ang-2/anti-VEGF bispecific monoclonal antibodies, gene therapy, etc.) at any time
  • Treatment with ocriplasmin (JETREA®) in the study eye at any time

NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
660 participants (actual)

Study arms

  • Active comparator
    aflibercept Q8

    Administered every 8 weeks after a loading phase

    Drug: aflibercept

  • Experimental
    High-Dose aflibercept Q12

    Administered every 12 weeks after a loading phase

    Drug: High-dose aflibercept

  • Experimental
    High-Dose aflibercept Q16

    Administered every 16 weeks after a loading phase

    Drug: High-dose aflibercept

Interventions

  • Intravitreally (IVT) administered as a liquid formulation in a vial

    Also known as: EYLEA®, BAY86-5321

  • Intravitreally (IVT) administered as a liquid formulation in a vial

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Percentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48

    The DRSS was assessed according to the following scale: 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.

    Time frame: Baseline, Week 48

  2. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 48

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). Only one study eye per participant was analyzed within the study

    Time frame: Baseline, Week 48

  3. Percentage of Participants With BCVA ≥69 Letters at Week 48

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

    Time frame: At Week 48

  4. Percentage of Participants Without Fluid at Foveal Center at Week 48

    Retinal fluid status was evaluated using spectral domain optical coherence tomography (SD-OCT) on the study eye.

    Time frame: At Week 48

  5. Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48

    Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Baseline, Week 48

  6. Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48

    Leakage is the release of fluorescein dye from diseased retinal vessels.

    Time frame: At Week 48

  7. Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48

    Vision-specific quality of life is assessed with the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire), i.e. a 25-item questionnaire that gives a score on a scale from 0 (worst) to 100 (best = no vision problems).

    Time frame: Baseline, Week 48

  8. Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48

    Concentrations of Free Aflibercept in Plasma by Time and Treatment Group

    Time frame: Through Week 48

  9. Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per Statistical Analysis Plan (SAP) Version 2.0 Appendix 10.9 for US Only)

    Time frame: Baseline, Week 48

  10. Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per SAP Version 2.0 Appendix 10.9 for US Only)

    Time frame: Baseline, Week 48

  11. Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60

    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

    Time frame: Baseline, Week 60

  12. Assessment of Immunogenicity to Aflibercept by Measuring the Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Through Week 96

    Number of participants with pre-existing immunoreactivity and treatment-emergent ADA response reported

    Time frame: Through Week 96

  13. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96

    A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.

    Time frame: Through Week 96

  14. Number of Participants With Any Serious TEAE Through Week 96

    A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.

    Time frame: Through Week 96

  15. Number of Participants With Any TEAE Through Week 156

    TEAEs are defined as AEs starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days or week 156 visit, whichever was later.

    Time frame: Through Week 156

  16. Number of Participants With Any Serious TEAE Through Week 156

    Time frame: Through Week 156

07

Results

Posted Nov 21, 2023

Participant flow

Main Study (Up to Wk 96)
Participant flow — Main Study (Up to Wk 96)
MilestoneAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
Started167329164000
Treated167328163000
Completed week 48157300156000
Completed week 60155289152000
Completed139256139000
Not completed287325000
Withdrew: Non-compliance with protocol by the subject210000
Withdrew: Adverse event192000
Withdrew: Decision by the investigator/sponsor293000
Withdrew: Withdrawal by subject9178000
Withdrew: Lost to follow-up5197000
Withdrew: Death9185000
Extension Phase (Wk 96 to Wk 156)
Participant flow — Extension Phase (Wk 96 to Wk 156)
MilestoneAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
Started0007013065
Completed0005810349
Not completed000122716
Withdrew: Protocol violation000100
Withdrew: Adverse event000111
Withdrew: Decision by the investigator/sponsor000032
Withdrew: Withdrawal by subject0005105
Withdrew: Lost to follow-up000366
Withdrew: Death000272

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48
LettersAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 488.67 ± 0.738.10 ± 0.617.23 ± 0.71
Statistical analysis
  • Aflibercept 2 mg Every 8 Weeks (2q8) vs High-dose (HD) Aflibercept Every 12 Weeks (HDq12) · Mixed Model for Repeated Measurements · p = <0.0001 · Least square (ls) mean difference: -0.57 · 95% CI -2.26 to 1.13HDq12 minus 2q8
  • Aflibercept 2 mg Every 8 Weeks (2q8) vs HD Aflibercept Every 16 Weeks (HDq16) · Mixed Model for Repeated Measurements · p = 0.0031 · Ls mean difference: -1.44 · 95% CI -3.27 to 0.39HDq16 minus 2q8
SecondaryPercentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48

The DRSS was assessed according to the following scale: 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48
Percentage of ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Percentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 4826.629.019.6
Statistical analysis
  • Aflibercept 2 mg Every 8 Weeks (2q8) vs High-dose (HD) Aflibercept Every 12 Weeks (HDq12) · Adjusted difference (%): 1.98 · 95% CI -6.61 to 10.57Difference with confidence interval (CI) was calculated using Mantel-Haenszel weighting scheme adjusted for stratification factors
  • Aflibercept 2 mg Every 8 Weeks (2q8) vs HD Aflibercept Every 16 Weeks (HDq16) · Adjusted difference (%): -7.52 · 95% CI -16.88 to 1.84Difference with confidence interval (CI) was calculated using Mantel-Haenszel weighting scheme adjusted for stratification factors
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 48

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). Only one study eye per participant was analyzed within the study

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 48
Percentage of ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 4823.018.716.6
SecondaryPercentage of Participants With BCVA ≥69 Letters at Week 48

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

Time frame:
At Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With BCVA ≥69 Letters at Week 48
Percentage of ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Percentage of Participants With BCVA ≥69 Letters at Week 4863.065.362.6
SecondaryPercentage of Participants Without Fluid at Foveal Center at Week 48

Retinal fluid status was evaluated using spectral domain optical coherence tomography (SD-OCT) on the study eye.

Time frame:
At Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Fluid at Foveal Center at Week 48
Percentage of ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Percentage of Participants Without Fluid at Foveal Center at Week 4854.558.543.8
SecondaryChange From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48

Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Microns
Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48
MicronsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48-164.85 ± 8.79-176.77 ± 5.73-148.84 ± 9.45
SecondaryPercentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48

Leakage is the release of fluorescein dye from diseased retinal vessels.

Time frame:
At Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48
Percentage of ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 482.57.60.7
SecondaryChange From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48

Vision-specific quality of life is assessed with the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire), i.e. a 25-item questionnaire that gives a score on a scale from 0 (worst) to 100 (best = no vision problems).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48
Score on a ScaleAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 482.82 ± 1.104.06 ± 0.802.94 ± 0.93
SecondarySystemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48

Concentrations of Free Aflibercept in Plasma by Time and Treatment Group

Time frame:
Through Week 48
Reported as:
Mean · milligram/Litre (mg/L)
Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48
milligram/Litre (mg/L)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 480.00102 ± 0.005800.0111 ± 0.01570.00105 ± 0.00477
SecondaryChange From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per Statistical Analysis Plan (SAP) Version 2.0 Appendix 10.9 for US Only)

Time frame:
Baseline, Week 48
Reported as:
Mean · Letters
Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA
LettersAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA9.11 ± 8.949.14 ± 8.359.11 ± 7.30
SecondaryChange From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per SAP Version 2.0 Appendix 10.9 for US Only)

Time frame:
Baseline, Week 48
Reported as:
Mean · Letters
Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA
LettersAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA1.63 ± 6.651.68 ± 5.541.64 ± 4.75
SecondaryChange From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60

Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

Time frame:
Baseline, Week 60
Reported as:
Least squares mean · Letters
Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60
LettersAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 609.40 ± 0.778.52 ± 0.637.64 ± 0.75
SecondaryAssessment of Immunogenicity to Aflibercept by Measuring the Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Through Week 96

Number of participants with pre-existing immunoreactivity and treatment-emergent ADA response reported

Time frame:
Through Week 96
Reported as:
Count of participants · Participants
Assessment of Immunogenicity to Aflibercept by Measuring the Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Through Week 96
ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Pre-existing Immunoreactivity4112
Treatment-Emergent274
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96

A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.

Time frame:
Through Week 96
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96
ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96134277143
SecondaryNumber of Participants With Any Serious TEAE Through Week 96

A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.

Time frame:
Through Week 96
Reported as:
Count of participants · Participants
Number of Participants With Any Serious TEAE Through Week 96
ParticipantsAflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)
Number of Participants With Any Serious TEAE Through Week 96468144
SecondaryNumber of Participants With Any TEAE Through Week 156

TEAEs are defined as AEs starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days or week 156 visit, whichever was later.

Time frame:
Through Week 156
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE Through Week 156
Participants2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
Number of Participants With Any TEAE Through Week 1566412259
SecondaryNumber of Participants With Any Serious TEAE Through Week 156
Time frame:
Through Week 156
Reported as:
Count of participants · Participants
Number of Participants With Any Serious TEAE Through Week 156
Participants2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
Number of Participants With Any Serious TEAE Through Week 156274122

Adverse events

Collected over From first study treatment through week 156. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2 mg Every 8 Weeks (2q8)9/167 (5.4%)46/167 (27.5%)98/167 (58.7%)
HD Aflibercept Every 12 Weeks (HDq12)18/328 (5.5%)84/328 (25.6%)190/328 (57.9%)
HD Aflibercept Every 16 Weeks (HDq16)5/163 (3.1%)45/163 (27.6%)116/163 (71.2%)
2q8/HD Aflibercept (Extension)2/70 (2.9%)27/70 (38.6%)50/70 (71.4%)
HDq12 Aflibercept (Extension)7/130 (5.4%)46/130 (35.4%)99/130 (76.2%)
HDq16 Aflibercept (Extension)3/65 (4.6%)23/65 (35.4%)50/65 (76.9%)
Most frequent serious events
Showing 10 of 216
Most frequent serious events
EventAflibercept 2 mg Every 8 Weeks (2q8)HD Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
SepsisInfections and infestations4/1672/3280/1633/701/1300/65
PneumoniaInfections and infestations1/1676/3280/1630/704/1301/65
OsteomyelitisInfections and infestations0/1672/3280/1630/704/1300/65
CellulitisInfections and infestations2/1671/3282/1631/700/1302/65
Myocardial infarctionCardiac disorders3/1675/3283/1631/704/1301/65
Acute kidney injuryRenal and urinary disorders2/1677/3281/1631/704/1300/65
Cerebrovascular accidentNervous system disorders0/1673/3285/1631/703/1302/65
HyperkalaemiaMetabolism and nutrition disorders1/1670/3283/1631/701/1302/65
Diabetic footSkin and subcutaneous tissue disorders0/1672/3281/1630/704/1300/65
Acute myocardial infarctionCardiac disorders2/16710/3282/1631/702/1300/65
Most frequent other events
Showing 10 of 36
Most frequent other events
EventAflibercept 2 mg Every 8 Weeks (2q8)HD Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)2q8/HD Aflibercept (Extension)HDq12 Aflibercept (Extension)HDq16 Aflibercept (Extension)
COVID-19Infections and infestations15/16740/32826/1636/7019/13015/65
HypertensionVascular disorders22/16735/32831/1636/7021/13013/65
Cataract Study EyeEye disorders5/16718/32818/1638/7018/13010/65
Cataract Fellow EyeEye disorders8/16717/32814/1637/7018/1308/65
NasopharyngitisInfections and infestations9/16721/32810/1635/7016/1304/65
InfluenzaInfections and infestations6/1675/3283/1635/705/1307/65
Vitreous haemorrhage Fellow EyeEye disorders5/1677/3286/1636/708/1303/65
Punctate keratitis Study EyeEye disorders1/1675/3287/1631/703/1305/65
Retinal haemorrhage Study EyeEye disorders1/1670/3286/1631/701/1305/65
Vitreous floaters Fellow EyeEye disorders4/1674/3288/1632/703/1305/65

Baseline characteristics

Full analysis set (FAS): All randomized participants who received at least 1 dose of study drug; it was based on the treatment assigned to the participant at baseline (as randomized). Only one study eye per participant was analyzed within the study.

Age, Continuous
Age, Continuous(Years)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)Total
Mean63.0 ± 9.7862.1 ± 11.1361.9 ± 9.5062.3 ± 10.41
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)Total
Female7511864257
Male9221099401
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)Total
Hispanic or Latino315434119
Not Hispanic or Latino133266126525
Unknown or Not Reported38314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)Total
American Indian or Alaska Native0202
Asian304823101
Black or African American1835962
Native Hawaiian or Other Pacific Islander0101
White112231128471
Multiple0101
Other46111
Not Reported3429
Best Corrected Visual Acuity (BCVA) in the Study Eye
Best Corrected Visual Acuity (BCVA) in the Study Eye(Letters)Aflibercept 2 mg Every 8 Weeks (2q8)High-dose (HD) Aflibercept Every 12 Weeks (HDq12)HD Aflibercept Every 16 Weeks (HDq16)Total
Mean61.5 ± 11.2263.6 ± 10.1061.4 ± 11.7662.5 ± 10.86
08

Study locations

138 sites
  • Regeneron Study Site
    Phoenix, Arizona 85021, United States
  • Regeneron Study Site
    Arcadia, California 91006, United States
  • Regeneron Study Site
    Beverly Hills, California 90211, United States
  • Regeneron Study Site
    Campbell, California 95008, United States
  • Regeneron Study Site
    Encino, California 91436, United States
  • Regeneron Study Site
    Fullerton, California 92835, United States
  • Regeneron Study Site
    Huntington Beach, California 92647, United States
  • Regeneron Study Site
    Long Beach, California 90807, United States
  • Regeneron Study Site
    Palo Alto, California 94303, United States
  • Regeneron Study Site
    Pasadena, California 91107, United States
  • Regeneron Study Site
    Poway, California 92064, United States
  • Regeneron Study Site
    Rancho Cordova, California 95670, United States
  • Regeneron Study Site
    Riverside, California 92505, United States
  • Regeneron Study Site
    Torrance, California 90509, United States
  • Regeneron Study Site
    Colorado Springs, Colorado 80909, United States
  • Regeneron Study Site
    Durango, Colorado 81301, United States
  • Regeneron Study Site
    Lakewood, Colorado 80228, United States
  • Regeneron Study Site
    Waterford, Connecticut 06385, United States
  • Regeneron Study Site
    Clearwater, Florida 33761, United States
  • Regeneron Study Site
    Fort Lauderdale, Florida 33308, United States
  • Regeneron Study Site
    Fort Myers, Florida 33912, United States
  • Regeneron Study Site
    Jacksonville, Florida 32216, United States
  • Regeneron Study Site
    Lakeland, Florida 33805, United States
  • Regeneron Study Site
    Largo, Florida 33770, United States
  • Regeneron Study Site
    Melbourne, Florida 32901, United States
  • Regeneron Study Site
    Miami, Florida 33126, United States
  • Regeneron Study Site
    Orlando, Florida 32806, United States
  • Regeneron Study Site
    Pinellas Park, Florida 33782, United States
  • Regeneron Study Site
    Plantation, Florida 33324, United States
  • Regeneron Study Site
    St. Petersburg, Florida 33711, United States
  • Regeneron Study Site
    Stuart, Florida 34994, United States
  • Regeneron Study Site
    Winter Haven, Florida 33880, United States
  • Regeneron Study Site
    Augusta, Georgia 30909, United States
  • Regeneron Study Site 1
    Marietta, Georgia 30060, United States
  • Regeneron Study Site 2
    Marietta, Georgia 30060, United States
  • Regeneron Study Site
    ‘Aiea, Hawaii 96701, United States
  • Regeneron Study Site
    Oak Forest, Illinois 60452, United States
  • Regeneron Study Site
    Springfield, Illinois 62703, United States
  • Regeneron Study Site
    Springfield, Illinois 62704, United States
  • Regeneron Study Site
    Carmel, Indiana 46290, United States
  • Regeneron Study Site
    Shawnee Mission, Kansas 66204, United States
  • Regeneron Study Site
    Baltimore, Maryland 21209, United States
  • Regeneron Study Site
    Hagerstown, Maryland 21740, United States
  • Regeneron Study Site
    Boston, Massachusetts 02114, United States
  • Regeneron Study Site
    Royal Oak, Michigan 48073, United States
  • Regeneron Study Site
    Southaven, Mississippi 38671, United States
  • Regeneron Study Site
    Henderson, Nevada 89052, United States
  • Regeneron Study Site
    Bloomfield, New Jersey 07003, United States
  • Regeneron Study Site
    Edison, New Jersey 08820, United States
  • Regeneron Study Site
    Teaneck, New Jersey 07666, United States
  • Regeneron Study Site
    Great Neck, New York 11021, United States
  • Regeneron Study Site
    Liverpool, New York 13088, United States
  • Regeneron Study Site
    New York, New York 11221, United States
  • Regeneron Study Site
    Oceanside, New York 11572, United States
  • Regeneron Study Site
    Shirley, New York 02114, United States
  • Regeneron Study Site
    Asheville, North Carolina 28803, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28210, United States
  • Regeneron Study Site
    Beachwood, Ohio 44122, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45202, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45242, United States
  • Regeneron Study Site
    Cleveland, Ohio 44130, United States
  • Regeneron Study Site
    Dublin, Ohio 43016, United States
  • Regeneron Study Site
    Edmond, Oklahoma 73013, United States
  • Regeneron Study Site
    Tulsa, Oklahoma 74114, United States
  • Regeneron Study Site
    Portland, Oregon 97225, United States
  • Regeneron Study Site
    Bethlehem, Pennsylvania 18017, United States
  • Regeneron Study Site
    Kingston, Pennsylvania 18704, United States
  • Regeneron Study Site
    Monroeville, Pennsylvania 15146, United States
  • Regeneron Study Site
    Beaufort, South Carolina 29902, United States
  • Regeneron Study Site
    Ladson, South Carolina 29456, United States
  • Regeneron Study Site
    West Columbia, South Carolina 29169, United States
  • Regeneron Study Site
    Rapid City, South Dakota 57701, United States
  • Regeneron Study Site
    Germantown, Tennessee 38138, United States
  • Regeneron Study Site
    Knoxville, Tennessee 37922, United States
  • Regeneron Study Site
    Nashville, Tennessee 37203, United States
  • Regeneron Study Site
    Abilene, Texas 79606, United States
  • Regeneron Study Site
    Bellaire, Texas 77401, United States
  • Regeneron Study Site 2
    San Antonio, Texas 78240, United States
  • Regeneron Study Site
    The Woodlands, Texas 77384, United States
  • Regeneron Study Site
    Willow Park, Texas 76087, United States
  • Regeneron Study Site 1
    Salt Lake City, Utah 84107, United States
  • Regeneron Study Site
    Fairfax, Virginia 22031, United States
  • Regeneron Study Site
    Norfolk, Virginia 23502, United States
  • Regeneron Study Site
    Morgantown, West Virginia 26506, United States
  • Regeneron Study Site
    Calgary, Alberta T2H 0C8, Canada
  • Regeneron Study Site
    Mississauga, Ontario L4W 1W9, Canada
  • Regeneron Study Site
    North York, Ontario M3C 0G9, Canada
  • Regeneron Study Site
    Sherbrooke, Quebec J1G 2V4, Canada
  • Regeneron Study Site
    Pardubice, 530 02, Czechia
  • Regeneron Study Site
    Prague, 100 34, Czechia
  • Regeneron Study Site
    Prague, 128 08, Czechia
  • Regeneron Study Site
    Prague, 150 00, Czechia
  • Regeneron Study Site
    Neubrandenburg, Mecklenburg-Westfalen 17036, Germany
  • Regeneron Study Site
    Göttingen, North Rhine-Westphalia 37075, Germany
  • Regeneron Study Site
    Münster, North Rhine-Westphalia 48145, Germany
  • Regeneron Study Site 1
    Pécs, Baranya H-7621, Hungary
  • Regeneron Study Site
    Szombathely, Vas County H-9700, Hungary
  • Regeneron Study Site
    Zalaegerszeg, Zala County H-8900, Hungary
  • Regeneron Study Site
    Budapest, H-1085, Hungary
  • Regeneron Study Site
    Budapest, H-1106, Hungary

Showing the first 100 of 138 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Loewenstein A, Schmidt-Ott U, Do DV, Lanzetta P, Leal S, Berliner AJ, Chu KW, Barakat MR, Ghorayeb G, Stewart MW, Spitzer MS, Zhang X, McCullough A, Tueckmantel C, Avila D, Morgan-Warren P, Brunck L, Dupljak A, Hymowitz M, Portnoy A, Gale R. Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON. Ophthalmol Ther. 2026 Jul;15(7):2441-2456. doi: 10.1007/s40123-026-01424-y. Epub 2026 Jun 13. PubMed 42287526 ↗
  • Suzuma K, Murata T, Shimura M, Yoshida S, Kishino G, Berliner AJ, Chu KW, Reed K, Vitti R, Cheng Y, Voronca D, Bhore R, Leal S, Morgan-Warren P, Schulze A, Schmidt-Ott U, Kobayashi M, Sakamoto T; PHOTON Investigators. Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial. Jpn J Ophthalmol. 2026 Jan;70(1):123-138. doi: 10.1007/s10384-025-01271-7. Epub 2025 Dec 26. PubMed 41452566 ↗
  • Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD; PHOTON Investigators. Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology. 2026 May;133(5):577-588. doi: 10.1016/j.ophtha.2025.10.028. Epub 2025 Nov 10. PubMed 41223900 ↗
  • Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. PubMed 38461843 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2022, 23 months.

Results were first posted in Nov 2023, 1 year 5 months after primary completion. A results delay was requested in May 2023.

Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jun 12, 2020
StartActual
Jun 29, 2020
Primary completionActual
May 30, 2022
CompletionActual
Jun 18, 2024
Results delay requested
May 19, 2023
Results first posted
Nov 21, 2023
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04429503
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jun 29, 2020
Primary completion
May 30, 2022
Completion
Jun 18, 2024
Results posted
Nov 21, 2023
Last update
Aug 8, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion